Premium
4. Pharmaceutical properties of fluticasone propionate nasal drops: a new formulation
Author(s) -
Denyer S.
Publication year - 1999
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1999.tb05033.x
Subject(s) - fluticasone propionate , nasal spray , medicine , dosage form , fluticasone , drug delivery , nasal administration , pharmacology , chemistry , surgery , corticosteroid , organic chemistry
A variety of corticosteroid delivery systems have been considered for the treatment of nasal polyposis. Safety considerations favour local delivery of the drug to the nasal cavity. No topical delivery system is entirely without problems, however, and formulations must address issues of microbiological quality, drug stability, reproducible drug delivery and adequate drug distribution at site, while also offering environmental and patient acceptability. Fluticasone propionate has been formulated in a new nasal drop preparation. As a highly water‐insoluble compound, the active fluticasone propionate requires microniza‐tion to an optimal particle size and subsequent dispersion with a surface‐active wetting agent. The product is presented in a unit dose low‐density polyethylene container, manufactured by a blow‐fill‐seal process and stored in an aluminium foil overwrap. Micronized active has been used to promote optimal local drug delivery, and excipients have been selected for low irritancy potential and high formulation stability. There is no microbiological risk with fluticasone propionate unit dose nasal drops 400 μg and therefore no need to include a preservative in the preparation. They provide a convenient and effective treatment option for patients with nasal polyposis.